$0.07—Stale · unknown old
NASDAQ • Last print unknown ago
$0.07—Stale · unknown old
VBI Vaccines Inc. is a biotechnology company focused on developing innovative vaccines for infectious diseases and cancer. Its lead product candidate, a therapeutic vaccine for glioblastoma, is currently in clinical trials, positioning the company in a niche market with high unmet medical needs.
VBI Vaccines aims to generate revenue through the commercialization of its vaccine products, particularly targeting high-value markets such as oncology and infectious diseases. The company leverages its proprietary technology platform, which enhances immune responses, giving it a competitive edge in vaccine efficacy.
Clinical trial results for lead product candidates, particularly the glioblastoma vaccine
Partnership announcements or collaborations with larger pharmaceutical companies
Regulatory approvals or advancements in the clinical pipeline
Market sentiment towards biotech sector performance
Regulatory changes impacting vaccine approval processes
Technological disruption in vaccine development methodologies
Emergence of new competitors with advanced vaccine technologies
Potential for larger pharmaceutical companies to dominate the market
High debt levels relative to equity, raising concerns about financial stability
Negative operating cash flow indicating reliance on external funding
low - The demand for vaccines is generally less sensitive to economic cycles, as healthcare spending tends to be more stable.
Moderate - Higher interest rates could increase the cost of financing for R&D, impacting cash flow and operational capacity.
minimal - The company is not heavily reliant on credit markets, but its high debt-to-equity ratio indicates potential vulnerability in tighter credit conditions.
growth - Investors seeking high-risk, high-reward opportunities in the biotech sector may find VBI appealing due to its innovative pipeline.
high - The stock has shown significant volatility, with a 1-year return of -94.6%, indicating high risk.